GlassScriptPhysician profile
Rahul Raghu
NPI 1689025512
$5,169.48
in general payments reported to CMS, 2019-2025
23 companies · $812 in 2025
The $812 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $241 · 2021: $621 · 2022: $654 · 2023: $1,684 · 2024: $694 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164 · Education: $26.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,164.15 |
| Education | $26.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,600.33 | 2022-2025 | |
| Alcon Vision LLC | $694.45 | 2019-2025 | Rocklatan, Voyager Dslt, Tryptyr |
| Allergan, INC. | $400.66 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $395.61 | 2022-2024 | Lumera 700, Veracity Surgical |
| Bausch & Lomb Americas INC. | $314.93 | 2022-2025 | Miebo, Xiidra, Alrex |
| Sun Pharmaceutical Industries INC. | $260.60 | 2023-2025 | Cequa |
| Glaukos Corporation | $228.13 | 2020-2021 | |
| Oyster Point Pharma, INC. | $198.71 | 2022-2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $160.65 | 2025 | Acthar |
| Sight Sciences, INC. | $137.93 | 2021-2024 | Omni Surgical System |
| Thea Pharma INC. | $134.88 | 2023-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $134.20 | 2022-2024 | |
| Regeneron Pharmaceuticals, INC. | $130.40 | 2019 | |
| Aerie Pharmaceuticals, INC. | $113.77 | 2019-2021 | |
| Harrow Eye, LLC | $63.94 | 2025 | Iheezo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $42.97 | 2024 | Humphrey Hfa, Cirrus Hd-Oct, Clarus |
| Biotissue Holdings INC. | $33.47 | 2022 | |
| Amgen INC. | $28.11 | 2025 | Tepezza |
| Ivantis, INC | $26.89 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $21.87 | 2019 | |
| Dompe US, INC. | $19.88 | 2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $13.60 | 2023 | Rayone Aspheric, Rayone Emv, Omidria |
| Tarsus Pharmaceuticals, INC. | $13.50 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Raghu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.